Best Researcher Award
| Andrew Plodkowski |
| Affiliation |
Memorial Sloan Kettering Cancer Center |
| Country |
United States |
| Scopus ID |
57211748497 |
| Documents |
84 |
| Citations |
9,922 |
| h-index |
39 |
| Subject Area |
Diagnostic Tools |
| Event |
Global Diseases Research Awards |
Andrew Plodkowski of Memorial Sloan Kettering Cancer Center, United States, is recognized for his contributions to clinical research and diagnostic innovation within oncology. The Best Researcher Award highlights his scholarly excellence and impactful role in advancing scientific knowledge through translational medicine. His academic and clinical work focuses on the development and refinement of diagnostic tools that enhance accuracy in disease detection and support more precise, evidence-based clinical decision-making. Through sustained engagement in multidisciplinary research, he has contributed to improving patient outcomes and strengthening the integration of research findings into practical oncology care, reflecting a strong commitment to scientific progress and medical advancement.
Abstract
This article presents a scholarly overview of Andrew Plodkowski’s academic and research contributions in the field of diagnostic tools. His research activity reflects a consistent focus on improving clinical methodologies and enhancing disease detection frameworks. The Best Researcher Award highlights his academic influence, interdisciplinary collaboration, and measurable scientific output within a leading cancer research institution [2].
Keywords
Diagnostic Tools, Cancer Research, Clinical Innovation and Translational Medicine
Introduction
The field of diagnostic medicine continues to evolve through advancements in imaging, biomarker identification, and computational analysis. Within this context, Andrew Plodkowski’s contributions at Memorial Sloan Kettering Cancer Center represent a sustained effort toward improving diagnostic precision. His research aligns with global priorities in early disease detection and clinical efficiency.
Research Profile
Andrew Plodkowski’s research profile reflects extensive engagement in clinical oncology and diagnostic innovation. With a Scopus-indexed output of 84 documents and over 9,922 citations, his scholarly presence demonstrates significant academic reach and interdisciplinary collaboration. His h-index of 39 further indicates consistent research influence within the scientific community [1].
Research Contributions
His research contributions include advancements in imaging-based diagnostics, clinical evaluation frameworks, and data-driven oncology methodologies. These efforts support improved patient stratification and treatment planning in complex disease environments.
Publications
The publication record of Andrew Plodkowski spans peer-reviewed journals focused on oncology, radiology, and diagnostic science. His work contributes to the broader scientific discourse on precision medicine and clinical decision support systems.
Research Impact
The impact of his research is evident in citation metrics and its application in clinical settings. His contributions support improved diagnostic accuracy and have influenced methodological approaches in medical imaging and oncology research.
Award Suitability
The Best Researcher Award recognizes individuals with sustained scholarly excellence and measurable scientific impact. Andrew Plodkowski’s research output, citation profile, and institutional affiliation position him as a strong candidate for recognition under the Global Diseases Research Awards framework [3].
Conclusion
In conclusion, Andrew Plodkowski’s academic contributions reflect a sustained commitment to advancing diagnostic science. His work continues to support innovation in clinical research and reinforces the importance of evidence-based approaches in modern healthcare systems.
External Links
References
- Elsevier. (n.d.). Scopus author details: Andrew Plodkowski, Author ID 57211748497. Scopus.
https://www.scopus.com/authid/detail.uri?authorId=57211748497
- Global Diseases Research Awards. (n.d.). Official Award Framework and Research Recognition Guidelines.
https://globaldiseases.org/
- Arbour, K. C., Mezquita, L., Long, N., Rizvi, H., Auclin, E., Ni, A., Martínez-Bernal, G., Ferrara, R., Lai, W. V., Hendriks, L. E. L., Sabari, J. K., Caramella, C., Plodkowski, A. J., Halpenny, D., Chaft, J. E., Planchard, D., Riely, G. J. (2018). Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non–small-cell lung cancer.
https://doi.org/10.1200/JCO.2018.79.0006
-
Derosa, L., Hellmann, M. D., Spaziano, M., Halpenny, D., Fidelle, M., Rizvi, H., Long, N., Plodkowski, A. J., Arbour, K. C., Chaft, J. E., Rouche, J. A., Zitvogel, L., Zalcman, G., Albiges, L., Escudier, B., Routy, B. (2018). Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer.
https://doi.org/10.1200/JCO.2018.79.0005
-
Drilon, A., Rekhtman, N., Arcila, M. E., Wang, L., Ni, A., Albano, M., Van Voorthuysen, M., Somwar, R., Smith, R. S., Montecalvo, J., Plodkowski, A. J., Ginsberg, M. S., Riely, G. J., Rudin, C. M., Ladanyi, M., Kris, M. G. (2016). Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: An open-label, single-centre, phase 2, single-arm trial.
https://doi.org/10.1056/NEJMoa1502309